Summary
Nitrates are highly effective both in terminating acute attacks of angina pectoris and in the prophylaxis of symptomatic and asymptomatic myocardial ischemia. Preload reduction by venodilatation is the prevailing mechanism of nitrates in patients with chronic stable angina and is the unique feature distinguishing them from beta and calcium-channel blockers. Nitrates dilate coronary arteries not only in pre- and poststenotic vessels, but also in eccentric lesions. In patients with endothelial dysfunction, nitrates seem to be the physiological substitute for endothelium-derived relaxing factor. During the past decade, however, there has been substantial evidence of a clinically relevant loss of the anti-ischemic effects (“nitrate tolerance”). Many studies with oral dosing of isosorbide dinitrate or isosorbide-5-mononitrate at least three times daily have proven nitrate tolerance in patients with coronary artery disease and/or congestive heart failure. Complete loss of anti-ischemic effects after repetitive, continuous patch attachments has also been found. As we first showed in 1983, intermittent therapy with once-daily ingestion of high-dose sustained-release isosorbide dinitrate was successful in preventing the development of tolerance. Similarly, tolerance to isosorbide-5-mononitrate also does not develop when it is ingested once daily. It is now generally accepted that a daily low-nitrate interval is required to prevent tolerance development. Although the minimal patch-free interval required to prevent tolerance needs further investigation, a 12-h patch-free interval should prevent tolerance in most patients. The prolonged duration of action of once-daily high-dosage administration of sustained-release formulations, the improved patient compliance with a single daily administration, and the increased likelihood of maximal anti-ischemic effects are important reasons for recommending high single daily doses of isosorbide dinitrate or isosorbide-5-mononitrate.
Similar content being viewed by others
References
Brunton TL (1867) Use of nitrate of amyl in angina pectoris. Lancet II: 97–98
Murrel W (1879) Nitro-glycerine as a remedy for angina pectoris. Lancet I: 80–81
Davis JA, Wiesel BH, Epstein SE (1955) The treatment of angina pectoris with nitroglycerin ointment. Am J Med Sci 230: 259–263
Carr CJ (1985) History of the synthesis and pharmacology of isosorbide dinitrate. Am Heart J 110: 197–201
Needleman P, Jakschik B, Johnson EM Jr (1973) Sulfhydryl requirement for relaxation of vascular smooth muscle. J Pharmacol Exp Ther 187: 324–331
Chasseaud LF (1983) Newer aspects of the pharmacokinetics of organic nitrates. Z Kardiol 72 [Suppl 3]: 20–23
Fung HL (1985) Pharmacokinetics and pharmacodynamics of isosorbide dinitrate. Am Heart J 110: 213–216
Stauch M, Grewe N, Nissen H (1975) Die Wirkung von 2- und 5-Isosorbid-mononitrat auf das Belastungs-EKG von Patienten mit Koronarinsuffizienz. Verh Dtsch Ges Kreislaufforsch 41: 182 (Abstract)
Michel D (1976) Beurteilung der Wirkung von Mononitraten mittels Ergometrie. In: Rudolph W, Siegenthaler W (eds) Nitrate, Wirkung auf Herz und Kreislauf. Urban und Schwarzenberg, Munich Baltimore Vienna, pp 132–134
Major RM, Taylor T, Chasseaud LF, Darragh A (1984) Isosorbide-5-mononitrate kinetics. Clin Pharmacol Ther 35: 653–659
Rietbrock N, Knoll J, Merz PG, Menke G (1985) Bioverfügbarkeit von Isosorbiddinitrat und Isosorbid-5-mononitrat unter steady-state-Bedingungen. Dtsch Med Wochenschr 110: 1821–1825
Eggeling T, Osterspey A, Geppert R, Jansen W (1985) Antianginöse Wirksamkeit von retardiertem Isosorbid-5-Mononitrat bei Patienten mit koronarer Herzkrankheit. In: Borchard U, Rafflenbeul W, Schrey A (eds) Mononitrat. Universitätsdruk-kerei Wolf, Munich, pp 76–87
Becker H-J, Schmidt W, Giersch K-H, Schneider HT (1987) Langzeitwirksamkeit und Verträglichkeit retardierten Isosor- bid-5-nitrats (100 mg) bei ambulanten Patienten mit stabiler Angina pectoris. Herz Kreislauf 19: 497–501
Bramann HU, Große-Heitmeyer W, Wisotzki R (1987) 24-h Wirkungsprofil von 60 mg retardiertem Isosorbid-Mononitrat bei Patienten mit koronarer Herzkrankheit. Med Welt 38: 1248–1252
Schmidt EG, Schmidt E (1987) Vergleich der klinischen Wirksamkeit von 40 mg und 60 mg retardiertem Isosorbid-5-Mononitrat bei Patienten mit koronarer Herzkrankheit. Herz Kreislauf 19: 444–449
Schulze H-O, Köhl M, Schmidt W, Ansmann EB (1987) Behandlung der stabilen Angina pectoris. Ergebnisse einer Studie über Wirksamkeit und Verträglichkeit retardierten Isosorbid-5-Nitrats (100 mg). Münch Med Wochenschr 129: 732–735
Reifart N, Reifart F, Kaltenbach M, Bussmann WD (1981) Vergleich der antianginösen Wirksamkeit und Wirkdauer von oral verabreichtem Isosorbiddinatrat (ISDN), Isosorbid-2-Mononitrat (IS-2-MN) und Isosorbid-5-Mononitrat (IS-5-MN). Med Welt 32: 524–526
Jansen W, Osterspey A, Metternich M et al (1983) Fehlende Toleranzentwicklung unter chronischer Behandlung mit täglich 60 mg Isosorbiddinitrat oder 60 mg 5-Isosorbid-mononitrat. Herz Kreislauf 15: 338–353
Schoeller R, Huckauf H, Rennhak V, Riebesel T, Brüggemann T, Biamino G (1983) Äquivalenz von Isosorbiddinitrat und Isosorbid-5-Mononitrat auf die belastungsinduzierte Ischämiere-aktion im EKG. Z Kardiol 72 [Suppl 2]: 70
Abrams J (1980) Nitrate tolerance and dependence. Am Heart J 99: 113–123
Schrey A (1981) Toleranz bei Nitropräparaten? Med Klin 76: 699–702
Rudolph W, Blasini R, Reiniger G, Brügmann U (1983) Tolerance development during isosorbide dinitrate treatment: can it be circumvented? Z Kardiol 72 [Suppl 3]: 195–198
Silber S (1984) Nitrattoleranz Pro und Contra. Dtsch Med Wochenschr 29: 1124–1132
Leier CV (1985) Nitrate tolerance. Am Heart J 110: 224–232
Parker JO (1985) Efficacy of nitroglycerin patches: facts of fancy? Ann Intern Med 102: 548–550
Abrams J (1986) Tolerance to organic nitrates. Circulation 74: 1181–1184
Charash B, Scheidt SS (1986) The controversy over transdermal nitroglycerin: an update. Am Heart J 112: 207–215
Kaltenbach M, Schneider W (1986) Fortbestehen der antiangionösen Wirksamkeit unter chronischer Nitrattherapie trotz Aufhebung hämodynamischer Teileffekte. Dtsch Med Wochenschr 111: 383–386
Winsor T, Berger HJ (1975) Oral nitroglycerin as a prophylactic antianginal drug: clinical, physiologic, and statistical evidence of efficacy based on a three-phase experimental design. Am Heart J 90: 611–626
Schang SJ, Pepine CJ (1977) Transient asymptomatic ST-segment depression during daily activity. Am J Cardiol 39: 396–402
Distante A, Maseri A, Severi S (1979) Management of vasospastic angina at rest with continuous infusion of isosorbide dinitrate: a double-cross-over study on a coronary care unit. Am J Cardiol 44: 533–539
Pepine CJ, Feldman RL, Ludbrook P et al (1986) Left ventricular dyskinesia reversed by intravenous nitroglycerin: a manifestation of silent myocardial ischemia. Am J Cardiol 58: 38B-42B
Arnim TV, Erath A, Reuschel-Janetschek E (1988) Isosorbide-5-mononitrate and nifedipine can reduce ischaemic ST-segment changes during Holter monitoring in patients with spontaneous angina pectoris. Eur Heart J 9 [Suppl A]: 113–118
Shell WE, Kivowitz CF, Rubins SB, See J (1986) Mechanisms and therapy of silent myocardial ischemia: the effect of transdermal nitroglycerin. Am Heart J 112: 222–229
Rezakovic DE, Pavicic L, Majacic M (1988) A randomized placebo controlled, double-blind, crossover trial of transdermal nitroglycerin in stable angina pectoris. Eur Heart J 9 [Suppl A]: 73–81
Schneeweiss A, Marmor A (1988) Transdermal nitroglycerin patches for silent myocardial ischemia during antianginal treatment. Am J Cardiol 61: 36E-38E
Nabel EG, Barry J, Rocco MB, Mead K, Selwyn AP (1989) Effects of dosing intervals on the development of tolerance to high dose transdermal nitroglycerin. Am J Cardiol. 63: 663–669
Chatterjee K (1987) Role of nitrates in silent myocardial ischemia. Am J Cardiol 60: 18H-25H
Frishman WH, Teicher M (1987) Antianginal drug therapy for silent myocardial ischemia. Am Heart J 114: 140–147
Zelis R, Mason DT (1975) Isosorbide dinitrate. Effect on the vasodilator response to nitroglycerin. JAMA 234: 166–170
Crawford MH, Amon KW (1982) Effect of nitrate on determinants of myocardial oxygen consumption during exercise. Int J Cardiol 1: 307–314
Loos DF, Schneider R, Schörner W (1983) Change in regional body blood volume caused by nitroglycerin. Z Kardiol 72 [Suppl 3]: 29–32
Strohm WD, Rahn R, Cordes H-J, Kurtz W, Kober G (1983) Diameters of abdominal veins and arteries during nitrate therapy. Z Kardiol 72 [Suppl 3]: 56–61
Crean PA, Crow J, Davies GJ (1984) Sequential changes in ventricular function following intravenous isosorbide dinitrate. Vase Med 205–208
Bassenge E, Strein K (1986) Dose-dependent effects of isosorbide-5-mononitrate on the venous, arterial and coronary arterial system of conscious dogs. Naunyn Schmiedebergs Arch Pharmacol 334: 100–104
Kingma I, Smiseth OA, Belenkie I et al (1986) A mechanism for nitroglycerin-induced downward shift of the left ventricular diastolic pressure-diameter relation. Am J Cardiol 57: 673–677
Schneider W, Tessmer G, Strohm WD, Kaltenbach M, Kober G (1986) Die Weite von arteriellen und venösen Abdominalgefäßen unter akuter und chronischer Gabe von Nitraten. Eine sonographische Untersuchung. Z Kardiol 75: 296–302
Goldberg RK, Lee RW, Olajos M, Goldman S (1987) Development of tolerance to nitroglycerin in the arterial and venous circulation of dogs. J Am Coll Cardiol 10: 1335–1341
Ganz W, Marcus HS (1972) Failure of intracoronary nitroglycerin to alleviate pacing-induced angina. Circulation 46: 880–889
Fuchs RM, Brinker JA, Guzman PA, Kross DE, Yin FCP (1983) Regional coronary blood flow during relief of pacing-induced angina by nitroglycerin. Implications for mechanism of action. Am J Cardiol 51: 19–23
Yokota M, Tsunekawa A, Miyahara T et al (1986) Effects of isosorbide-5-mononitrate on exercise-induced hemodynamic changes in angina pectoris. Am J Cardiol 58: 53–58
Sorensen SG, Ritchie JL, Caldwell JH, Hamilton GW, Kennedy JW (1980) Serial exercise radionuclide angiography. Validation of count-derived changes in cardiac output and quantitation of maximal exercise ventricular volume change after nitroglycerin and propranolol in normal men. Circulation 61: 600–609
Battock DG, Levitt PW, Steele PP (1976) Effects of isosorbide dinitrate and nitroglycerin on central circulatory dynamics in coronary artery disease. Am Heart J 92: 455–458
Salel AF, Berman DS, DeNardio GL, Mason DT (1976) Radionuclide assessment of nitroglycerin influence on abnormal left ventricular segmental contraction in patients with coronary heart disease. Circulation 53: 975–982
Ritchie JL, Sorensen SG, Kennedy JW, Hamilton GW (1979) Radionuclide angiography: noninvasive assessment of hemodynamic changes after administration of nitroglycerin. Am J Cardiol 43: 278–284
Pfisterer M, Glans L, Burkart F (1983) Comparative effects of nitroglycerin, nifedipine and metoprolol on regional left function in patients with one-vessel coronary disease. Circulation 67: 291–301
Kaski JC, Plaza LR, Meran DO, Araujo L, Chierchia S, Maseri A (1985) Improved coronary supply: prevailing mechanism of action of nitrates in chronic stable angina. Am Heart J 110: 238–245
Silber S, Vogler AC, Spiegelsberger F, Vogel M, Theisen K (1988) The insufficient nitrate response: patients' characterization and response to beta and calcium blockade. Eur Heart J 9 [Suppl A]: 125–134
Yamagishi T, Uki K, Yamauchi M et al (1986) Acute effects of sublingual isosorbide dinitrate on global and regional left ventricular diastolic filling in normal persons. Am J Cardiol 58: 1061–1066
Steele PP, Rainwater J, Jensen D, Vogel R, Battock D (1978) Isosorbide dinitrate-induced improvement in left ventricular ejection fraction during exercise in coronary arterial disease. Chest 74: 526–530
Borer JS, Bacharach SL, Green MV, Kent KM, Johnston GS, Epstein SE (1978) Effect of nitroglycerin on exercise-induced abnormalities of left ventricular regional function and ejection fraction in coronary artery disease. Circulation 57: 314–320
Silber S, Krause KH, Garner C, Theisen K, Jahrmärker H (1983) Anti-ischemic effects on an 80-mg tablet of isosorbide dinitrate in sustained-release form before and after 2 weeks treatment with 80 mg once-daily or twice-daily. Z Kardiol 72 [Suppl 3]: 211–217
Silber S, Vogler AC, Krause K-H, Vogel M, Theisen K (1987) Induction and circumvention of nitrate tolerance applying different dosage intervals. Am J Med 83: 860–870
Gray R, Chatterjee K, Vyden J, Ganz W, Forrester J, Swan H (1975) Hemodynamic and metabolic effects of isosorbide dinitrate in chronic congestive heart failure. Am Heart J 90: 346–352
Mikulic E, Franciosa JA, Cohn JN (1975) Comparative hemodynamic effects of chewable isosorbide dinitrate and nitroglycerin in patients with congestive heart failure. Circulation 52: 477–482
Franciosa JA, Cohn J (1980) Sustained hemodynamic effects without tolerance during long-term isosorbide dinitrate treatment of chronic left ventricular failure. Am J Cardiol 45: 648–654
Hecht HS, Karahalios SE, Schnugg SJ et al (1982) Improvement in supine bicycle exercise performance in refractory congestive heart failure after isosorbide dinitrate: radionuclide and hemodynamic evaluation of acute effects. Am J Cardiol 49: 133–140
Leier CV, Huss P, Magorien RD, Unverferth DV (1983) Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation 76: 817–822
Cohn JN (1985) Nitrates for congestive heart failure. Am J Cardiol 56: 19A-23A
Franciosa JA (1985) Isosorbide dinitrate and exercise performance in patients with congestive heart failure. Am Heart J 110: 245–250
Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M (1987) Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 317: 799–804
Cintron GB, Glasser SP, Weston BA et al (1988) Effect of intravenous isosorbide dinitrate versus nitroglycerin on elevated pulmonary arterial wedge pressure during acute myocardial infarction. Am J Cardiol 61: 21–25
Schneeweiss A (1988) Comparative evaluation of isosorbide-5-mononitrate and nitroglycerin in chronic congestive heart failure. Am J Cardiol 61: 19E-21E
Gensini GG, DiGiorgi S, Murad-Netto S, Black A (1962) Arteriographic demonstration of coronary artery spasm and its release after the use of a vasodilator in a case of angina pectoris and in the experimental animal. Angiology 13: 550–553
Likoff W, Kasparian H, Lehman JS, Segal BL (1964) Evaluation of coronary vasodilators by coronary angiography. Am J Cardiol 13: 7–9
Feldman RL, Pepine CJ, Conti CR (1981) Magnitude of dilatation of large and small coronary arteries by nitroglycerin. Circulation 64: 324–333
Brown BG (1985) Response of normal and diseased epicardial coronary arteries to vasoactive drugs: quantitative arteriographic studies. Am J Cardiol 56: 23E-29E
Rafflenbeul W, Urthaler F, Russell R, Lichtlen PR, James TN (1980) Dilatation of coronary artery stenoses after isosorbide dinitrate in man. Br Heart J 43: 546–549
Badger RS, Brown BG, Gallery CA, Bolson EL, Dodge HT (1985) Coronary artery dilatation and hemodynamic responses after isosorbide dinitrate therapy in patients with coronary artery disease. Am J Cardiol 56: 390–395
Gorlin R (1983) Dynamic vascular factors in the genesis of myocardial ischaemia. J Am Coll Cardiol 1: 897–906
Maseri A, Chierchia S, Kaski JC (1985) Mixed angina pectoris. Am J Cardiol 56: 30E-33E
Cohen MV, Downey JM, Sonnenblick EH, Kirk ES (1973) The effects of nitroglycerin on coronary collaterals and myocardial contractility. J Clin Invest 52: 2836–2847
Forman R, Eng C, Kirk ES (1983) Comparative effect of verapamil and nitroglycerin on collateral blood flow. Circulation 67: 1200–1204
Maseri A (1985) A review of nitrate therapy in stable angina, variant angina, unstable angina and myocardial infarction. Z Kardiol 74 [Suppl 4]: 1–3
Hill JA, Feldman RL, Pepine CJ, Conti CR (1982) Randomized double-blind comparison of nifedipine and isosorbide dinitrate in patients with coronary arterial spasm. Am J Cardiol 49: 431–438
Maseri A, Chierchia S, Davies GJ, Fox KM (1983) Variable susceptibility to dynamic coronary obstruction: an elusive link between coronary atherosclerosis and angina pectoris. Am J Cardiol 52: 46A-51A
Rafflenbeul W, Lichtlen PR (1983) Quantitative coronary angiography: evidence of a sustained increase in vascular smooth muscle tone in coronary artery stenoses. Z Kardiol 72 [Suppl 3]: 87–91
Erbel R, Huttemann M, Schreiner G, Darius N, Pop T, Meyer J (1987) Ischdmietoleranz des Herzens während perkutaner transluminaler Koronarangioplastie. Herz 12: 302–311
Lichtlen P, Halter J, Gattiker K (1974) The effect of isosorbide dinitrate on coronary blood flow, coronary resistance and left ventricular dynamics under exercise in patients with coronary artery disease. Basic Res Cardiol 49: 402
Cohn PF, Maddox D, Holman BL et al (1977) Effect of sublingually administered nitroglycerin on regional myocardial blood flow in patients with coronary artery disease. Am J Cardiol 39: 672–678
Rudolph W, Fleck E, Dirschinger J (1982) Wirkung antianginöser Substanzen auf die Myokarddurchblutung. Herz 7: 378–387
Engel HJ, Lichtlen PR (1981) Beneficial enhancement of coronary blood flow by nifedipine. Comparison with nitroglycerin and beta-blocking agents. Am J Med 71: 658–666
Tono-oka I, Satoh S, Kanaya T et al (1986) Alterations in myocardial perfusion during exercise after isosorbide dinitrate infusion in patients with coronary disease: assessment by thalium-201 scintigraphy. Am Heart J 111: 525–532
Stegaru B, Loose R, Keller H, Buss J, Wetzel E (1988) Effects of long-term treatment with 120 mg of sustained-release isosorbide dinitrate and 60 mg of sustained-release nifedipine on myocardial perfusion. Am J Cardiol 61: 74E-78E
De Caterina R, Giannessi D, Mazzone A, Bernini W (1988) Mechanisms for the in vivo antiplatelet effects of isosorbide dinitrate. Eur Heart J 9 [Suppl A]: 45–49
Schrör K, Ahland B, Weiss P, König E (1988) Stimulation of coronary vascular PGI2 by organic nitrates. Eur Heart J 9 [Suppl A]: 25–32
Stamler J, Cunningham M, Loscalzo J (1988) Reduced thiols and the effect of intravenous nitroglycerin on platelet aggregation. Am J Cardiol 62: 377–380
Levin RI, Jaffe EA, Weksler BB, Tack-Goldman K (1981) Nitroglycerin stimulates synthesis of prostacyclin by human endothelial cells. J Clin Invest 67: 762–769
Fitzgerald DJ, Roy L, Robertson RM, Fitzgerald GA (1984) The effect of organic nitrates on prostacyclin biosynthesis and platelet function in humans. Circulation 70: 297–302
Panzenbeck MJ, Baez A, Kaley G (1984) Nitroglycerin and nitroprusside increase coronary blood flow in dogs by a mechanism independent of prostaglandin release. Am J Cardiol 53: 936–940
Winniford MD, Jackson J, Malloy CR, Rehr RB, Campbell WB, Hillis D (1984) Does indomethacin attenuate the coronary vasodilatory effect of nitroglycerin? J Am Coll Cardiol 4: 1114–1117
Trimarco B, Cuocolo A, Van Dorne D et al (1985) Late phase of nitroglycerin-induced coronary vasodilatation blunted by inhibition of prostaglandin synthesis. Circulation 71: 840–848
Berenger FP, Friggi A, Bodard H, Rolland PH (1988) Control of the anti-thrombogenic endothelial cell defense by short- and long-term exposure of cultured endothelial cells to isosorbide nitrates. Eur Heart J 9 [Suppl A]: 3–9
Palmer RMJ, Ferrige AG, Moneada S (1987) Nitric oxide release accounts for the biological activity of endothelium derived relaxing factor. Nature 327: 524–526
Förstermann U, Mülsch A, Böhme E, Busse R (1986) Stimulation of soluble guanylate cyclase by acetylcholine-induced endothelium-derived factor from rabbit and canine arteries. Circ Res 58: 531–538
Francis GS (1988) Nitroglycerin, nitroprusside and endothelium-derived relaxing factor. J Am Coll Cardiol 11: 1325–1326
Griffith TM, Lewis MJ, Newby AC, Henderson AH (1988) Endothelium-derived relaxing factor. J Am Coll Cardiol 12: 797–806
Furchgott RF, Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373–376
Ludmer PL, Selwyn AP, Shook TL et al (1986) Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315: 1046–1051
Zeiher AM, Wollschlaeger H, Drexler H, Bonzel T (1988) Paradoxical vasoconstrictor response in angiographically normal coronary arteries in patients with CAD. Circulation 78: 11–103 (Abstract)
Bassenge E, Stewart DJ (1988) Interdependence of pharmacologically-induced and endothelium-mediated coronary vasodilation in antianginal therapy. Cardiovasc Drugs Ther 2: 27–34
Fricke G, Hild R, Ihm P, Modlmayr HH (1976) Feldstudie mit Isoket und Isoket retard. In: Rudolph W, Siegenthaler W (eds) Nitrate, Wirkung auf Herz and Kreislauf. Urban and Schwarzenberg, Munich Berlin Vienna, pp 151–160
Lange RL, Reid MS, Tresch DD, Keelan MH, Bernhard VM, Collidge G (1972) Nonatheromatous ischemic heart disease following withdrawal from chronic industrial nitroglycerin exposure. Circulation 46: 666–678
Klock JC (1975) Nonocclusive coronary disease after chronic exposure to nitrates: evidence for physiologic nitrate dependence. Am Heart J 89: 510–513
Stewart DD (1888) Remarkable tolerance of nitroglycerin. Polyclinic VI: 171–172
Stewart DD (1905) Tolerance to nitroglycerin. JAMA 44: 1678–1679
Schelling JL, Lasagna L (1967) A study of cross-tolerance to circulatory effects of organic nitrates. Clin Pharmacol Ther 3: 256–260
Danahy DT, Aronow WS (1977) Hemodynamics and antianginal effects of high dose oral isosorbide dinitrate after chronic use. Circulation 56: 205–212
Bogaert MG, De Schaepdryver AF (1968) Tolerance towards glyceryl trinitrate (Trinitrin) in dogs. Arch Int Pharmacodyn Ther 171: 221
Brunner D, Meshulam Z, Zerieker F (1974) Effectiveness of sustained-action isosorbide dinitrate on exercise-induced myocardial ischemia. Chest 66: 282–287
Blasini R, Brügmann U, Mannes A, Froer KL, Hall D, Rudolph W (1980) Wirksamkeit von Isosorbiddinitrat in retardierter Form bei Langzeitbehandlung. Herz 5: 298–305
Thadani U, Fung HL, Drake AC, Parker JO (1982) Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose-response relation during acute and sustained therapy. Am J Cardiol 49: 411–419
Parker JO, Fung HL, Ruggirello D, Stone JA (1983) Tolerance to isosorbide dinitrate: rate of development and reversal. Circulation 68: 1074–1080
Schneider WU, Bussmann WD, Stahl B, Kaltenbach M (1984) Dose-response relation of antianginal activity of isosorbide dinitrate. Am J Cardiol 53: 700–705
Jansen W, Osterspey A, Tauchert M et al (1982) 5-Isosorbid-mononitrat unter Ruhe- und Belastungsbedingungen bei koronarer Herzkrankheit. Dtsch Med Wochenschr 107: 1499–1506
Goldbarg AN, Moran JF, Butterfield TK, Nemickas R, Bermudez G (1969) Therapy of angina pectoris with propranolol and long-acting nitrates. Circulation 40: 847–853
Aronow WS, Chesluk HM (1970) Sublingual isosorbide dinitrate therapy versus sublingual placebo in angina pectoris. Circulation 41: 869–874
Livesley B, Catley PF, Campbell RC, Oram S (1973) Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris. Br Med J 1: 375–378
Schuster P, Trieb G, Wiechmann HW (1983) Hemodynamic effects of isosorbide-5-mononitrate in acute and chronic treatment of coronary heart disease. Z Kardiol 72 [Suppl 3]: 251–254
Davidov ME, Mroczek WJ (1977) Effect of sustained release nitroglycerin capsules on anginal frequency and exercise capacity. Angiology 28: 181–189
Parker JO, Koughnett KA van, Farrell B (1985) Comparison of buccal nitroglycerin and oral isosorbide dinitrate for nitrate tolerance in stable angina pectoris. Am J Cardiol 56: 724–728
Becker H-J, Walden G, Kaltenbach M (1976) Gibt es eine Tachyphylaxie beziehungsweise Gewöhnung bei der Behandlung der Angina pectoris mit Nitrokörpern? Verh Dtsch Ges Inn Med 82: 1208–1210
Lee G, Mason DT, Amsterdam EA, Miller RR, De-Maria AN (1978) Antianginal efficacy of oral therapy with isosorbide dinitrate capsules. Chest 73: 327–332
Schneider W, Wietschorek A, Bussmann WD, Kaltenbach M (1983) Sustained antianginal efficacy of oral high-dose isosorbide dinitrate in patients with coronary heart disease. Z Kardiol 72 [Suppl 3]: 259–267
Schwarzer C, Miczoch J (1982) Zur Frage der Toleranzentwicklung von Isosorbid-5-Mononitrat. Herz Kreislauf 14: 585–589
Cyran J, Grund R (1985) Untersuchungen der anti-anginbsen Langzeitwirkung und der Verträglichkeit von Isosorbid-5-Mononitrat bei Patienten mit koronarer Herzkrankheit und stabiler Angina pectoris im Rahmen einer multizentrischen Studie. In: Borchard U, Rafflenbeul W, Schrey A (eds) Mononitrat. Universitätsdruckerei Wolf, Munich, pp 162–174
Sehnert W (1985) Wirksamkeit und Verträglichkeit von 3 x 20 mg Isosorbid-5-Mononitrat (IS-5-MN) bei der Langzeittherapie der koronaren Herzkrankheit. In: Borchard U, Rafflenbeul W, Schrey A (eds) Mononitrat. Universitätsdruckerei Wolf, Munich, pp 144–160
Brunner D, Weisbord J (1985) Kontrollierte Studie mit Elantan 40 (Isosorbid-5-Mononitrat) - Wirksamkeit gemessen am Belastungs-EKG. In: Borchard U, Rafflenbeul W, Schrey A (eds) Mononitrat. Universitätsdruckerei Wolf, Munich, pp 135–142
Khurmi NS, Bowles MJ, Kohli RS, Raftery EB (1986) Does placebo improve indexes of effort-induced myocardial ischemia? An objective study in 150 patients with chronic stable angina pectoris. Am J Cardiol 57: 907–911
Glasser SP, Clark PI, Lipicky RJ, Yusuf S (1988) What is the risk of exposing patients with chronic stable exertional angina to placebo in controlled trials of new drugs? Circulation 78: II-99 (Abstract)
Crandall LA, Leake CD, Loevenhart AS, Muehlberger CW (1931) Acquired tolerance and cross tolerance between the nitrous and nitric acid esters and sodium nitrite in man. J Pharmacol Exp Ther 41: 103
Dalal JJ, Yao L, Parker JO (1983) Nitrate tolerance: influence of isosorbide dinitrate on the hemodynamic and antianginal effects of nitroglycerin. J Am Coll Cardiol 2: 115–120
Parker JO, Farrell B, Lahey KA, Moe G (1987) Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med 316: 1440–1444
Kohli RS, Rodrigues EA, Kardash MM, Whittington JR, Raftery EB (1986) Acute and sustained effects of isosorbide-5-mononitrate in stable angina pectoris. Am J Cardiol 58: 727–731
Natarajan D, Khurana TR, Karhade V, Nigam PD (1988) Sustained hemodynamic effects with therapeutic doses of intravenous nitroglycerin in congestive heart failure. Am J Cardiol 62: 319–321
Reichek N, Goldstein RE, Redwood DR, Epstein SE (1974) Sustained effects of nitroglycerin ointment in patients with angina pectoris. Circulation 50: 348–352
Handler CE, Sullivan ID (1985) Double-blind randomised crossover trial comparing isosorbide dinitrate cream and oral sustained-release tablets in patients with angina pectoris. Int J Cardiol 7: 149–156
Klein HO, Ninio R, Blank I et al (1986) Prolonged hemodynamic effect of a slow-release nitroglycerin ointment. Am J Cardiol 7:58: 436–442
Müller T, Imhof PR, Burkart F, Chu LC, Geradin A (1982) Human pharmacological studies of a new transdermal system containing nitroglycerin. Eur J Clin Pharmacol 22: 473–480
Karim A (1983) Transdermal absorption of nitroglycerin from microseal drug delivery (MDD) system. Angiology 34: 11–22
Heidemann R, Menke G, Letzel H, Rietbrock N (1985) Serumkonzentration von Glyceroltrinitrat (GTN) bei transdermaler Applikation von GTN-Pflastern unterschiedlicher Provenienz. Dtsch Med Wochenschr 110: 1568–1572
Abrams J (1984) The brief saga of transdermal nitroglycerin discs: paradise lost? Am J Cardiol 54: 220–224
Georgopoulos AJ, Markis A, Georgiadis H (1982) Therapeutic efficacy of anew transdermal system containing nitroglycerin in patients with angina pectoris. Eur J Clin Pharmacol 22: 481–485
Hollenberg M, Go M (1984) Efficacy of transdermal nitroglycerin patches in patients with angina pectoris. Cardiovasc Rev Rep 5: 328–340
Sharpe DN, Coxon R (1984) Nitroglycerin in a transdermal therapeutic system in chronic heart failure. J Cardiovasc Pharmacol 6: 76–82
Niestegge H, Cordes G, Blümchen G (1988) Toleranzentwicklung unter kontinuierlicher Nitroglycerin-Infusion. Herz 14: 66–70
Schneider W, Kett U, Kaltenbach M (1988) Antiischämische Wirkung einer 24 stündigen kontinuierlichen Infusion mit Glyceryltrinitrat bei Patienten mit stabiler Angina pectoris. Dtsch Med Wochenschr 113: 543–547
Zimrin D, Reichek N, Bogin KT, Aurigemma G, Douglas P, Berko B, Fung H-L (1988) Antianginal effects of intravenous nitroglycerin over 24 hours. Circulation 77: 1376–1384
Parker JO, Fung HL (1984) Transdermal nitroglycerin in angina pectoris. Am J Cardiol 54: 471–476
Reiniger G, Kraus F, Dirschinger J, Glasini R, Rudolph W (1985) Hochdosierte transdermale Nitroglycerintherapie: Wirkungsverlust innerhalb von 24 Stunden? Herz 10: 157–162
Reifart N, Bussmann W-D (1986) Placebo-kontrollierte Doppelblind-Studie zur antiischämischen Wirksamkeit und Wirkdauer von transdermalen Depotnitrat. Z Kardiol 75 [Suppl 3]: 83–85
Crean P, Ribero P, Crea F, Davies G, Ratcliffe D, Maseri A (1984) Failure of transdermal NTG to improve stable angina. Am Heart J 108: 1494–1500
Reichek N, Priest C, Zimrin D, Chandoler T, Sutton J (1984) Antianginal effects of nitroglycerin patches. Am J Cardiol 54: 1–7
Schneider W, Michel O, Kaltenbach M, Bussmann W-D (1985) Antianginöse Wirkung von transdermal appliziertem Nitroglycerin in Abhängigkeit von der Pflastergröße. Dtsch Med Wochenschr 110: 87–91
Colditz GA, Halvorsen KT, Goldhaber SZ (1988) Randomized clinical trials of transdermal nitroglycerin systems for the treatment of angina: a meta-analysis. Am Heart J 116: 174–180
Thompson RH (1983) The clinical use of transdermal delivery devices with nitroglycerin. Angiology 34: 23–31
Hubner PJB, Jones PRM, Galer IAR (1985) Assessment of dermal glyceryltrinitrate and isosorbide dinitrate for patients with angina pectoris. Br Med J 290: 514–516
James MA, Walker PR, Papouchado M, Wilkinson PR (1985) Efficacy of transdermal glyceryl drinitrate in the treatment of chronic stable angina pectoris. Br Heart J 53: 631–635
Osterspey A, Jansen W, Ulbrich T, Simon P, Tauchert M, Hilger HH (1984) Wirkung von Nitroglycerinpflastern auf Hämody-namik und Belastbarkeit von Patienten mit koronarer Herzkrankheit. Dtsch Med Wochenschr 109: 714–717
Scardi S, Pivotti F, Fonda F, Pandullo C, Castelli M, Pollavini G (1985) Effect of a new transdermal therapeutic system containing nitroglycerin on exercise capacity in patients with angina pectoris. Am Heart J 110: 546–551
Jordan RA, Seth L, Henry DA, Wilen MM, Franciosa JA (1985) Dose requirements and hemodynamic effects of transdermal nitroglycerin compared with placebo in patients with congestive heart failure. Circulation 71: 980–986
Agabiti E, Cerri B, Cefis M (1983) Dose-response study on Nitroderm TTS in angina pectoris. In: Bussman W-D, Taylor SH (eds) New horizons in nitrate therapy. Medizin Verlag, Mün-chen, pp 101–110
Jordan RA, Seth L, Casebolt P, Hayes MJ, Wilen MM, Franciosa J (1986) Rapidly developing tolerance to transdermal nitroglycerin in congestive heart failure. Ann Intern Med 104: 295–298
Smyth P, Akhras F, Jackson N, Silk B, Taylor SH (1986) Nitrate patches are ineffective in stable angina. Circulation 74: 11–138 (Abstract)
Muiesan G, Agabiti-Rosei E, Muiesan L et al (1986) A multicenter trial of transdermal nitroglycerin in exercise-induced angina: individual antianginal response after repeated administration. Am Heart J 112: 233–238
Greco R, D'Alterio D, Schiattarella M, Boccia A, Greco L, Marsico F (1988) Efficacy of a new transdermal nitroglycerin patch (Deponit 10) for stable angina pectoris. Am J Cardiol 61: 44E-51E
Parker JO, Koughnett KA van, Fung HL (1984) Transdermal isosorbide dinitrate in angina pectoris: effect of acute and sustained therapy. Am J Cardiol 54: 8–13
Luke R, Sharpe N, Coxon R (1987) Transdermal nitroglycerin in angina pectoris: efficacy of intermittent application. J Am Coll Cardiol 10: 642–646
Roth A, Kulick D, Freidenberger L, Hong R, Rahimtoola SH, Elkayam U (1987) Early tolerance to hemodynamic effects of high dose transdermal nitroglycerin in responders with severe chronic heart failure. J Am Coll Cardiol 9: 858–864
Sullivan M, Savvides M, Abouantoun S, Madsen EB, Froelicher V (1985) Failure of transdermal nitroglycerin to improve exercise capacity in patients with angina pectoris. Am J Cardiol 5: 1220–1223
Thadani U, Manyari D, Parker JO, Fung HL (1980) Tolerance to the circulatory effects of oral isosorbide dinitrate. Circulation 61: 526–535
Colucci WS, Williams GH, Alexander RE, Braunwald E (1981) Mechanisms and implications of vasodilator tolerance in the treatment of congestive heart failure. Am J Med 71: 89–99
Packer M, Meller J, Medina N, Yushak M, Gorlin R (1981) Determinants of drug responses in severe chronic heart failure. Activation of vasoconstrictor forces during vasodilatory therapy. Circulation 64: 506–514
Olivari M, Carlyle P, Levine BS, Cohn J (1983) Hemodynamic and hormonal response to transdermal nitroglycerin in normal subjects and in patients with congestive heart failure. J Am Coll Cardiol 2: 872–888
Kraupp O, Benke T, Placheta P et al (1980) Die Wirkung einer einmaligen sowie chronischen Verabreichung von Isoket auf die Plasma-Renin-Aktivität von Hunden. In: Rudolph W, Schrey A (eds) Nitrate 11, Wirkung auf Herz and Kreislauf. Urban and Schwarzenberg, Munich Baltimore Vienna, pp 17–20
Lis Y, Bennett D, Lambert G, Robson D (1984) A preliminary double-blind study of intravenous nitroglycerin in acute myocardial infarction. Intensive Care Med 10:179–184
Fahmy NR, Gavras HR (1985) Impact of captopril on hemodynamic and humoral effects of nitroprusside. J Cardiovasc Pharmacol 7: 869
Rajfer SI, Demma FJ, Goldberg LI (1984) Sustained beneficial hemodynamic response to large doses of transdermal nitroglycerin in congestive heart failure and comparison with intravenous nitroglycerin. Am J Cardiol 54: 120–125
Elkayam U, Roth A, Henriquez B, Weber L, Tonnemacher D, Rahimtoola SH (1985) Hemodynamic and hormonal effects of high-dose transdermal nitroglycerin in patients with chronic congestive heart failure. Am J Cardiol 56: 555–559
Packer M, Medina N, Yushak M, Lee WH (1986) Hemodynamic factors limiting the response to transdermal nitroglycerin in severe chronic congestive heart failure. Am J Cardiol 57: 260–267
Sharpe N, Coxon R, Webster M, Luke R (1987) Hemodynamic effects of intermittent transdermal nitroglycerin in chronic congestive heart failure. Am J Cardiol 59: 895–899
Schaer DH, Buff LA, Katz RJ (1988) Sustained antianginal efficacy of transdermal nitroglycerin patches using an overnight 10-hour nitrate-free interval. Am J Cardiol 61: 46–50
Herman AG, Bogaert MG (1971) Organic nitrates: tolerance at the level of the vascular smooth muscle. Arch Int Pharmacodyn Ther 192: 200–202
Needleman P, Johnson EM (1973) Mechanism of tolerance development of organic nitrates. J Pharmacol Exp Ther 184: 709–715
Münzel T, Steward DJ, Holtz J, Bassenge E (1988) Preferential venoconstriction by cyclooxygenase inhibition in vivo without attenuation of nitroglycerin venodilation. Circulation 78: 407–515
Böhme E, Graf H, Schultz G (1978) Effects of sodium nitroprusside and other smooth muscle relaxants on cyclic GMP formation in smooth muscle and platelets. Adv Cyclic Nucleotide Protein Phosphorylation Res 9: 131–143
Adelstein RS, Hathaway DR (1979) Role of calcium and cyclic adenosin 3′-5′-monophosphate in regulating smooth muscle contraction. Am J Cardiol 44: 783–787
Keith RA, Burkman AM, Sokoloski TD, Fertel RH (1983) Vascular tolerance to nitroglycerin and cyclic GMP generation in rat aortic smooth muscle. J Pharmacol Exp Ther 221: 525–531
Kukovetz WR, Holzmann S (1983) Mechanism of nitrate-induced vasodilatation and tolerance. Z Kardiol 72 [Suppl 3]: 14–19
Ignarro LJ, Gruetter C (1980) Requirement of thiols for activation of coronary arterial guanylate cyclase by glyceryl trinitrate and sodium nitrate: possible involvement ofS-nitrosothiols. Biochim Biophys Acta 631: 221–231
Winniford MD, Kennedy PL, Wells PJ, Hills LD (1986) Potentiation of nitroglycerin-induced coronary dilatation byN-acetyl-cysteine. Circulation 73: 138–142
Ignarro LJ, Lippton H, Edwards JC et al (1981) Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 218: 739–749
Torresi J, Horowitz JD, Dusting GJ (1985) Prevention and reversal of tolerance to nitroglycerine with N-acetylcysteine. J Cardiovasc Pharmacol 7: 777–783
Horowitz JD, Antmann EM, Lorell BH, Barry WH, Smith TW (1983) Potentiation of the cardiovascular effects of nitroglycerin byN-acetylcysteine. Circulation 68: 1247–1253
Horowitz JD, Henry CA, Syrjanen ML et al (1988) Combined use of nitroglycerin andN-acetylcysteine in the management of unstable angina pectoris. Circulation 77: 787–794
May DC, Popma JJ, Black WH et al (1987) In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries. N Engl J Med 317: 805–809
Parker JO, Farrell B, Lahey KA, Rose BF (1987) Nitrate tolerance: lack of effect ofN-acetylcysteine. Circulation 76: 572–576
Bertel O, Noll G, Marx BE (1988) Reversal of nitrate tolerance withN-acetylcysteine. N Engl J Med 318: 638
Münzel T, Holtz J, Mülsch A, Steward DJ, Bassenge E (1988) Nitrate tolerance in epicardial arteries not reversed by N-acetylcysteine (NAC) in vivo, but tolerance-independent interactions exist. Circulation 78: II-36 (Abstract)
Fung HL, Chong S, Kowaluk E, Hough K, Kakemi M (in press) Mechanisms for the pharmacologic interaction of organic nitrates with thiols: existence of an extracellular pathway for the reversal of nitrate vascular tolerance byN-acetylcysteine. J Pharmacol Exp Ther
Blasini R, Brügmann U, Reiniger C, Rudolph W (1985) Langzeittherapie der Belastungs-Angina-pectoris durch einmal tägliche Verabreichung von 120 mg Isosorbiddinitrat in retardierter Form. Herz 10: 163–171
Ohlmeier H, Mertens HM, Möller M, Mannebach H, Gleichmann U (1986) Vereinfachte Langzeittherapie der koronaren Herzkrankheit mit 120 mg retardiertem Isosorbiddinitrat ein mal tdglich. Untersuchung zur Wirkdauer und Toleranzentwicklung. Z Kardiol 75 [Suppl 3]: 50–56
Wortmann A, Bachmann K, Beuber HJ, Roth E (1986) Hämodynamik und Koronardynamik unter ISDN-Langzeitgabe. Z Kardiol 75 [Suppl 3]: 68–76
Hall D, Stautner C, Kraus F, Rudolph W (1986) Interval treatment of congestive heart failure with once-daily administration of 120 mg isosorbide dinitrate in sustained-release form: no evi dence of tolerance development during long-term therapy. In: Bussmann WD, Just HJ (eds) Vasoaktive Substanzen bei Herzinsuffizienz. Springer, Berlin Heidelberg New York, pp 23–26
Krepp HP (1985) Langzeitbehandlung der koronaren Herzerkrankung mit Elantan long. In: Borchard U, Rafflenbeul W, Schrey A (eds) Mononitrat. Universitätsdruckerei Wolf, Munich, pp 176–183
Kenedi P (1986) Intraindividuelle Dosiswirkungsbeziehung von Elantan long. Z Kardiol 75 [Suppl 3]: 77–79
Ahmadinejad M, Eghbal B, Sorgenich W, Schneeweiss A, Weiss M (1988) Slow-release isosorbide-5-mononitrate — a new once daily therapeutic modality for angina pectoris. Eur Heart J 9 [Suppl A]: 135–139
Rudolph W, Dirschinger J, Reiniger G, Beyerle A, Hall D (1988) When does nitrate tolerance develop? What dosages and which intervals are necessary to ensure maintained effectiveness? Eur Heart J 9 [Suppl A]: 63–72
Nyberg G (1987) Klinische Erfahrungen mit einem Isosorbidmononitrat in Duriles-Galenik (Coleb-Duriles). In: Grobecker H et al (eds) Chronische Nitrattherapie. Toleranz, Retardie rung, Stellenwert. Verlag für angewandte Wissenschaften, Munich, pp 81–94
Wisenberg G, Roks C, Nichol P, Goddard MD (1989) Sustained effect of and lack of development of tolerance to controlled-release isosorbide-5-mononitrate in chronic stable angina pectoris. Am J Cardiol 64: 569–576
Cowan JC, Bourke JP, Reid DS, Julian DG (1987) Prevention of tolerance to nitroglycerin patches by overnight removal. Am J Cardiol 60: 271–275
Reiniger G, Menke G, Boertz A, Kraus F, Rudolph W (1987) Intervalltherapie zur effektiven Behandlung der Angina pectoris mit Nitroglycerin-Pflastersystemen. Herz 12: 68–73
Juneau M, Gossard D, Waters D (1988) Limited usefulness of intermittent nitroglycerin patches in stable angina. Circulation 78: 11–327 (Abstract)
DeMots H, Glasser SP (1989) Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 13: 786–793
Miller ED Jr, Ackerly JA, Vaughan ED Jr, Peach MJ, Epstein RM (1977) The renin-angiotensin system during controlled hypotension with sodium nitroprusside. Anesthesiology 47: 257–262
Boerts A, Bonn R (1986) Nitrate therapy without loss of action by correct dosage. Z Kardiol 75 [Suppl 3]: 57–60
Thadani U, Hamilton SF, Olson E et al (1987) Duration of effects and tolerance of slow-release isosorbide-5-mononitrate for angina pectoris. Am J Cardiol 59: 756–762
Rennhak U, Riebesel T, Biamino G (1985) A double-blind cross-over study on the effectiveness and possible development of tolerance during long-term therapy with isosorbide-5-mono nitrate or isosorbide dinitrate slow-release in coronary artery disease. In: Cohn JN, Rittinghausen R (eds) Mononitrates. Springer, Berlin Heidelberg New York, pp 147–153
Thadani U, Prasad R, Hamilton SF et al (1987) Usefulness of twice-daily isosorbide-5-mononitrate in preventing development of tolerance in angina pectoris. Am J Cardiol 60: 477–482
Wolf R, Sinn R, Guillen R, Koeffler H (1981) Hämodynamische Langzeitwirkung von hochdosiertem Isosorbiddinitrat (80 mg) in Slow-Release-Form bei koronarer Herzerkrankung. Dtsch Med Wochenschr 106: 1130–1134
Udhoji VN, Heng MK (1984) Hemodynamic effects of highdose sustained-action oral isosorbide dinitrate in stable angina. Am J Cardiol 78: 234–240
Danahy DT, Burwell DT, Aronow WS, Prakash R (1977) Sustained hemodynamics and antianginal effect of high dose oral isosorbide dinitrate. Circulation 55: 381–387
Markis JE, Gorlin R, Millis RM, Williams RA, Schweitzer P, Ransil BJ (1979) Sustained effect of orally administered isosorbide dinitrate on exercise performance of patients with angina pectoris. Am J Cardiol 43: 265–271
Reiniger G, Glasini R, Brügmann U, Rudolph W (1984) Toleranzentwicklung hinsichtlich der antiischämischen Wirkung von Isosorbiddinitrat bei regelmäßiger, mehrfach täglicher Verabreichung. Herz 9: 146–152
Kenedi P, Giebler B (1983) Antianginal efficacy of long-term nitrate therapy. Z Kardiol 72 [Suppl 3]: 233–238
Silber S (1985) Retardierte Nitratformen. Dtsch Med Wochenschr 110: 776–777
Silber S, Vogler AC, Spiegelsberger F, Vogel M, Theisen K (1988) Antiischemic effects of a newly developed capsule containing 120 mg isosorbide dinitrate in sustained release form. Am J Cardiol 61: 1352–1353
Erlemeier HH, Kupper W, Lange S, Bleifeld W (1986) Oberprüfung der antianginösen Wirkung und Verträglichkeit von Isosorbid-5-Mononitrat oder Nifedipin in retardierter Form. Z Kardiol 75 [Suppl 3]: 112–114
Akhras F, Jefferies S, Jackson G (1985) Isosorbide-5-mononitrate — effective monotherapy in chronic stable angina. Z Kardiol 74 [Suppl 4]: 16–20
Kulick D, Roth A, McIntosh N, Rahimtoola SH, Elkayam U (1988) Resistance to isosorbide dinitrate in patients with severe chronic heart failure: incidence and attempt at hemodynamic prediction. J Am Coll Cardiol 12: 1023–1028
Agabiti-Rosei E, Muiesan ML, Beschi M et al (1987) Antianginal efficacy of transdermal nitroglycerin as related to adrenergic and renin-aldosterone systems. Circulation 76 [Suppl IV]: IV-128 (Abstract)
Packer M, Gottlieb SS, Kessler PD et al (1988) Overnight withdrawal of nitroglycerin therapy does not prevent the development of nitrate tolerance in severe heart failure. J Am Coll Cardiol 11: 43A (Abstract)
Reiniger G, Rudolph W (1985) Therapie der koronaren Herzerkrankung mit Nitroglycerinpflastern. Herz 10: 305–311
Ingendaay A, Klein G, Rehm KD, Töberich H, Vanscheidt W (1987) Vergleichende Pharmakokinetic retardierter Mononitratprdparate. Munch Med Wochenschr 129: 34–36
Silber S, Vogler AC, Vogel M, Theisen K (1989) A newly developed nitroglycerin patch with ‘phased release’. J Am Coll Cardiol 13 [Suppl A]: 231-A (Abstract)
Deanfield JE, Shea MJ, Selwyn AP (1985) Clinical evaluation of transient myocardial ischemia during daily life. Am J Med 79 [Suppl 3A]: 18–24
Nademanee K, Intarachot V, Josephson MA, Singh BN (1987) Circadian variation in occurrence of transient overt and silent myocardial ischemia in chronic stable angina and comparison with Prinzmetal angina in men. Am J Cardiol 60: 494–498
Rocco MB, Barry J, Campbell S et al (1987) Circadian variation of transient myocardial ischemia in patients with coronary artery disease. Circulation 75: 395–400
Willich SN, Levy D, Rocco MB, Tofler GH, Stone PH, Muller JE (1987) Circadian variation in the incidence of sudden cardiac death in the Framingham heart study population. Am J Cardiol 60: 801–806
Rogers WJ, Coggin CJ, Gersh BJ et al (1988) Ten year followup of quality of life in patients randomized to medicine vs. CABG: Coronary Artery Surgery Study (CASS). Circulation 78: II-258 (Abstract)
Silber S (1986) Wann ist ein Patient mit koronarer Herzerkrankung optimal behandelt? Internist 27: 525–540
Awan NA, Amsterdam EA, Vera Z, DeMaria AN, Miller RR, Mason DT (1976) Reduction of ischemic injury by sublingual nitroglycerin in patients with acute myocardial infarction. Circulation 54: 761–765
Fukuyama T, Schechtman KB, Roberts R (1980) The effects of intravenous nitroglycerin on hemodynamics, coronary blood flow and morphologically and enzymatically estimated infarct size in conscious dogs. Circulation 62: 1227–1238
Rabinowitz B, Tamaro I, Elazar E, Neufeld HN (1982) Intravenous isosorbide dinitrate in patients with refractory pump failure and acute myocardial infarction. Circulation 65: 771–778
Bussmann WD, Haller M (1983) Hinweis auf eine Abnahme der Früh- und Spätmortalität bei frischem Herzinfarkt unter Nitroglycerintherapie. Klin Wochenschr 61: 417–422
Bussmann WD, Gieberle B (1983) Beeinflußt eine Dauertherapie mit hochdosierten Nitraten die Prognose bei koronarer Herzkrankheit? Klin Wochenschr 61: 428
Flaherty JT, Becker LC, Bulkley BH et al (1983) A randomized prospective trial of intravenous nitroglycerin in patients with acute myocardial infarction. Circulation 68: 576–588
Osuna PP, Moreno LMG, Jimenez AA et al (1985) Isosorbide dinitrate sublingual therapy for inferior myocardial infarction: randomized trial to assess infarct size limitation. Am J Cardiol 55: 330–334
Jugdutt BI, Warnica JW (1988) Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage and infarct location. Circulation 78: 906–919
Rapaport E (1985) Influence of long-acting nitrate therapy on the risk of reinfarction, sudden death, and total mortality in survivors of acute myocardial infarction. Am Heart J 110: 276–280
Yusuf S, Collins R, MacMahon S, Peto R (1988) Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomized trials. Lancet I: 1088–1092
Cohn JN, Archibald DG, Ziesche S et al (1986) Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration cooperative study. N Engl J Med 314: 1547–1552
Cohn PF (1980) Silent myocardial ischemia in patients with a defective anginal warning system. Am J Cardiol 45: 697–702
Silber S, Vogler A (1986) Die stumme Myokardischämie: Dimensionierung eines Problems. Intensivmedizin 23: 52–63
Rozanski A, Bairey CN, Krantz DS et al (1988) Mental stress and the induction of silent myocardial ischemia in patients with coronary artery disease. N Engl J Med 318: 1005–1012
Malliani A (1986) The elusive link between transient myocardial ischemia and pain. Circulation 73: 201–204
Sheps DS, Adams KF, Hinderliter A et al (1987) Endorphins are related to pain perception in coronary artery disease. Am J Cardiol 59: 523–527
Falcone C, Sconocchia R, Guasti L, Codega S, Montemartini C, Specchia G (1988) Dental pain threshold and angina pectoris in patients with coronary artery disease. J Am Coll Cardiol 12: 348–352
Cohn PF (1988) Silent myocardial ischemia. Ann Intern Med 109: 312–317
DeWood MA, Rozanski A (1986) Long-term prognosis of patients with and without silent ischemia. Circulation 74 [Suppl II]: II-59 (Abstract)
Gottlieb SO, Weisfeldt ML, Ouyang P, Mellits ED, Gerstenblith G (1986) Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med 314: 1214–1219
Rocco MB, Nabel EG, Campbell S et al (1988) Prognostic importance of myocardial ischemia detected by ambulatory monitoring in patients with stable coronary artery disease. Circulation 78: 877–884
Tzivoni D, Gavish A, Zin D et al (1988) Prognostic significance of ischemic episodes in patients with previous myocardial infarction. Am J Cardiol 62: 661–664
Weiner DA, Ryan TJ, McCabe CH et al (1988) Comparison of coronary artery bypass surgery and medical therapy in patients with exercised-induced silent myocardial ischemia: a report from the Coronary Artery Surgery Study (CASS) registry. J Am Coll Cardiol 12: 595–599
Geft IL, Fishbein MC, Ninomiyal K et al (1982) Intermittent brief periods of ischemia have a cumulative effect and may cause myocardial necrosis. Circulation 66: 1150–1153
Cannon PJ, Connell PA, Stockley IH, Garner ST, Hampton JR (1988) Prevalence of angina as assessed by a survey of prescriptions for nitrates. Lancet I: 979–981
Stone PH, Glasser SP, Young P et al (1988) Inability to predict the presence of silent ischemia in patients with stable angina and a positive exercise test. Circulation 78: II-332 (Abstract)
Bajaj R, Silber S (1988) Digital Holter monitoring of extent and duration of ischemic episodes is more reliable than analog recording. Circulation 78 [Suppl]: II-579 (Abstract)
Silber S, Vogler AC, Speigelsberger F, Vogel M, Theisen K (1988) Validation of digital Holter ST segment analysis. J Ambulatory Monitoring 1: 145–152
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Silber, S. Nitrates: Why and how should they be used today?. Eur J Clin Pharmacol 38 (Suppl 1), S35–S51 (1990). https://doi.org/10.1007/BF01417564
Issue Date:
DOI: https://doi.org/10.1007/BF01417564